ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Jardiance commercial milestone collaboration revenue by Year
Jardiance commercial milestone collaboration revenue ($M) ($M)
Eli Lilly Jardiance commercial milestone collaboration revenue: $200M in FY2025.
Latest, FY2025
200
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 10-K (filed 2026-02-12)
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-12) ↗
Reported in Form 10-Q / 10-K Note 2.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Jardiance commercial milestone collaboration revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 200 | – | Form 10-K (filed 2026-02-12) ↗ |
Cite this data
StockData. (2026). Eli Lilly Jardiance commercial milestone collaboration revenue ($M), annual FY2025–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-jardiance-milestone
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.